Inventor · disambiguated record
Lisa Dietz
Also filed as: DIETZ LISA
16 granted patents·19 pending applications·31 citations·filing 2014–2024
89Inventor score
Top patents by PatentIndex Score
35 records- 0195US11478554B2Antibody drug conjugates (ADCS) having enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Oct 25, 2022·5 cites·20 claims
- 0291US11660351B2Antibody drug conjugates (ADCs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted May 30, 2023·5 cites·50 claims
- 0390US12195448B2Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2023·Granted Jan 14, 2025·4 cites·18 claims
- 0489US11071788B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodiesBayer Pharma AG·Filed 2016·Granted Jul 27, 2021·6 cites·32 claims
- 0587US11685714B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted Jun 27, 2023·3 cites·30 claims
- 0678US10150773B2N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2016·Granted Dec 11, 2018·3 cites·8 claims
- 0778US9422285B2Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereofBayer Pharma AG·Filed 2014·Granted Aug 23, 2016·4 cites·13 claims
- 0875US2023338559A1Antibody drug conjugates (adcs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 0975US2025026737A1Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2024·Application pending·0 cites
- 1073US12059472B2Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBAYER AG·Filed 2017·Granted Aug 13, 2024·1 cites·15 claims
- 1172US12138256B2Treatment of cardiopulmonary disordersBAYER AG·Filed 2023·Granted Nov 12, 2024·0 cites·30 claims
- 1270US2024043379A1Prodrugs of cytotoxic active agents having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1369US2025090519A1Treatment of cardiopulmonary disordersBAYER AG·Filed 2024·Application pending·0 cites
- 1465US2022362392A1Specific antibody drug conjugates (adcs) having ksp inhibitorsBayer Pharma AG·Filed 2022·Application pending·0 cites
- 1561US11433140B2Specific antibody drug conjugates (ADCs) having KSP inhibitorsBayer Pharma AG·Filed 2017·Granted Sep 6, 2022·0 cites·9 claims
- 1656US2025281480A1Pharmaceutical dry powder inhalation formulationBAYER AG·Filed 2022·Application pending·0 cites
- 1751US2024051935A1Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2021·Application pending·0 cites
- 1850US2024109864A1Substituted pyrazolyl piperidine carboxylic acidsBAYER AG·Filed 2021·Application pending·0 cites
- 1950US2024101528A1Substituted pyrazolo piperidine carboxylic acidsBAYER AG·Filed 2021·Application pending·0 cites
- 2046US2016176880A1Substituted imidazo[1,2-a]pyrazinecarboxamides and use thereofBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2142US10214526B2Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereofBayer Pharma AG·Filed 2016·Granted Feb 26, 2019·0 cites·18 claims
- 2239US11136296B2Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereofBAYER AG·Filed 2018·Granted Oct 5, 2021·0 cites·13 claims
- 2339US2018318438A1Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodiesBayer Pharma AG·Filed 2016·Application pending·0 cites
- 2438US11149018B2Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereofBAYER AG·Filed 2018·Granted Oct 19, 2021·0 cites·12 claims
- 2536US10292970B2Heteroaryl-substituted imidazo[1,2-A]pyridines and their useBayer Pharma AG·Filed 2015·Granted May 21, 2019·0 cites·6 claims
- 2636US10174021B2Substituted pyrazolo[1,5-A]pyridines and their useBayer Pharma AG·Filed 2015·Granted Jan 8, 2019·0 cites·7 claims
- 2735US2017101407A16-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulatorsBayer Pharma AG·Filed 2015·Application pending·0 cites
- 2835US2017050962A1Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseasesBayer Pharma AG·Filed 2015·Application pending·0 cites
- 2934US9771360B2Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their useBayer Pharma AG·Filed 2015·Granted Sep 26, 2017·0 cites·7 claims
- 3034US2017233345A1Substituted quinoline-4-carboxamides and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3134US2017240566A1Amino-substituted annulated pyrimidines and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3234US2017233413A1Substituted annulated pyrimidines and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3334US2017057958A1Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3433US2017050961A1Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2015·Application pending·0 cites
- 3533US2017057954A1Substituted imidazo[1,2-a]pyridinecarboxamides and their useBayer Pharma AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lisa Dietz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →